EGFR and cancer: The absence of a response of R-SI NTSR1 tumors to erlotinib or metformin, as shown in figure 6C, is consistent with the presence of a NTS autocrine loop, leading to the sustained activation of EGFR and responsible for cancer cell aggressiveness.